COVID-19 Mortality Rates and Outcomes for HIV Patients Better Than HIV-Negative Group
Small study shows HIV patients not at a greater risk for worse outcomes.
Read More
California PrEP Push Reveals Underserved Demographics
The California PrEP Assistance Program, established to remove financial and structural barriers to PrEP access, had positive but uneven initial results.
The Burden of Multidrug-Resistant HIV
With fostemsavir now available for patients with few options, an expert discusses what challenges MDR-HIV patients face in their care.
Urine HIV Self-Testing in China Shows Effectiveness
With insufficient HIV diagnosis testing in that country, this novel testing could help it reach part of its UNAIDS 90-90-90 targets.
First Possible HIV Remission Case without Bone Marrow Transplant Observed
A 34-year-old Brazilian man's HIV was undetectable 57 weeks after ending a heightened regimen of ART.
Fostemsavir Benefits Multi-Drug Resistant HIV
A look at the BRIGHTE study data which evidenced the recently FDA-approved add-on agent.
Switching to Second-Line Therapy Versus First-Line Antiretroviral
In low-level HIV-1 viraemia patients, this strategy demonstrated viral suppression in more than half of a study's participants.
Survey: Two-Thirds of US Adults Have Not Received HIV Testing
Despite being recommended at least once among all persons aged 13-64 years old by the CDC, notably few respondents have ever been tested for HIV.
Combatting Virologic Failure in Children with HIV using Targeted Drug Resistance Testing
Guidelines recommend concentrated adherence counseling and frequent viral load testing for virologic failure, but drug resistance testing is often excluded.
Eight-Week Cabotegravir Injection Has HIV PrEP Potential
Interim analysis shows a long-acting injectable was associated with fewer HIV infections than daily oral PrEP in a diverse population of HIV-risk participants.
Doravirine Benefits HIV-1 Patients with Common RAMs
A retrospective analysis of the DRIVE-FORWARD and DRIVE-AHEAD trials shows treatment-naive patients particularly fared well from the novel agent.
Gaining Insights into Islatravir and Doravirine
Carey Hwang, MD, PhD, executive director and product development lead, Global Clinical Development of Infectious Disease at Merck spoke with Contagion® regarding the therapies and went further into depth about the studies.
UNAIDS Report: Inequality and Coronavirus Risk a Decade of HIV Progress
A report released for AIDS 2020 warns the international AIDS response could be set back substantially by ongoing events.
Clinics Test Long-Acting HIV Therapy Implementation Strategies in Cabotegravir-Rilpivirine Trial
CUSTOMIZE was designed to identify methods of implementing an experimental once-monthly, long-acting regimen antiretroviral therapy against HIV-1 into clinical practice.
Using A "Kick and Kill" Approach to Cure HIV
Investigators report results of the first randomized clinical trial to test a novel strategy to wake up and kill dormant HIV hiding in reservoir cells.
2-Drug HIV Regimen Comparable to 3-Drug Regimen in Treatment-Naïve Patients
Dolutegravir and lamivudine combination regimen met primary endpoint in 2 phase 3 studies of treatment-naïve patients with HIV.
Long-Term Immune Response Data for Investigational HIV Vaccine Revealed
Mosaic-based vaccine regimen maintained humoral and cellular HIV immune responses according to long-term data from APPROACH.
IAS-USA Releases 2018 Guidelines for HIV Treatment and Prevention
New guidelines on the prevention and treatment of HIV in adults from the IAS-USA Panel highlight advances made since the 2016 guidelines, as well as the need for new strategies.
Achieving Undetectable Viral Load On ART Renders Individuals Sexually Non-Infectious
PARTNER 2 study reports zero HIV transmissions over 8 years in gay couples who did not use condoms and had achieved an undetectable viral load on HIV treatment.
